SONM · DNA X, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Due to the uncertainty of whether the note will be converted or of the Company obtaining additional financing, there is substantial doubt regarding the Company’s ability to continue as a going concern as of the date of the filing of this 10-Q.”View the 10-Q filed May 20, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Oct 27, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Oct 27, 2025.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Capital Markets — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SONM
this stock
DNA X, Inc.
|
$5.16M | +10.7% | -37.7% | — | 4.0% |
|
MS
Morgan Stanley
|
$341.82B | +22.4% | +5.5% | 17.6 | 0.8% |
|
GS
Goldman Sachs Group Inc
|
$302.65B | +18.3% | +8.9% | 16.0 | 2.1% |
|
SCHW
Schwab Charles Corp
|
$189.09B | +11.2% | +22.0% | 19.9 | 1.2% |
|
HOOD
Robinhood Markets, Inc.
|
$85.92B | -15.5% | +51.6% | 42.3 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Oct 27, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SONM | -7.8% | +2.8% | -33.7% | +2.8% | +10.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -8.2% | -1.6% | -47.5% | -1.2% | -3.2% |